Plasma Platelet-activating Factor (PAF) Levels and Desmopressin Response in Children with Hemophilia A and von Willebrand's Disease

Plasma Platelet-activating Factor (PAF) Levels and Desmopressin Response in Children with Hemophilia A and von Willebrand's Disease -

[1]  G. Siest,et al.  Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[2]  G. Lip,et al.  Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. , 1997, The American journal of cardiology.

[3]  A. Rumley,et al.  Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[4]  T. Makris,et al.  Haemostasis balance disorders in patients with essential hypertension. , 1997, Thrombosis research.

[5]  P. Mannucci.  Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. , 1997, Blood.

[6]  S. Julius,et al.  Heart rate and the cardiovascular risk , 1997, Journal of hypertension.

[7]  V. Praloran,et al.  PAF and hematopoiesis. VIII. Biosynthesis and metabolism of PAF by human bone marrow stromal cells. , 1996, Experimental hematology.

[8]  I. Mattiasson,et al.  Coagulation and fibrinolytic factors in normotensive hypertension-prone men , 1996, Journal of hypertension.

[9]  G. Zimmerman,et al.  Platelet‐activating factor: a mediator for clinicians , 1995, Journal of internal medicine.

[10]  P. Lund-johansen,et al.  The Bergen Blood Pressure Study: prehypertensive changes in cardiac structure and function in offspring of hypertensive families. , 1995, Blood pressure.

[11]  J. Lusher.  Response to 1-deamino-8-D-arginine vasopressin in von Willebrand disease. , 1994, Haemostasis.

[12]  M. Woodward,et al.  Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. , 1993, British heart journal.

[13]  P. Ganz,et al.  Platelet‐activating factor secreted by DDAVP‐treated monocytes mediates von willebrand factor release from endothelial cells , 1993, Journal of cellular physiology.

[14]  J. Feldman,et al.  Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. , 1991, American heart journal.

[15]  U. Smith,et al.  Elevated fibrinogen and plasminogen activator inhibitor (PAI‐1) in hypertension are related to metabolic risk factors for cardiovascular disease , 1990, Journal of internal medicine.

[16]  H. Salari.  Solid-phase extraction and reversed-phase high-performance liquid chromatographic technique for isolation and estimation of platelet activating factor in plasma. , 1986, Journal of chromatography.